Pfizer (PFE) Gets a Hold Rating from Goldman Sachs

Goldman Sachs analyst Terence Flynn maintained a Hold rating on Pfizer (PFEResearch Report) yesterday and set a price target of $40.00. The company’s shares closed last Friday at $37.13.

According to TipRanks.com, Flynn is a 4-star analyst with an average return of 12.9% and a 65.2% success rate. Flynn covers the Healthcare sector, focusing on stocks such as Arvinas Holding Company, United Therapeutics, and Eli Lilly & Co.

Pfizer has an analyst consensus of Moderate Buy, with a price target consensus of $41.83, a 12.6% upside from current levels. In a report issued on December 28, RBC Capital also maintained a Hold rating on the stock with a $42.00 price target.

See today’s analyst top recommended stocks >>

Based on Pfizer’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $12.13 billion and net profit of $2.19 billion. In comparison, last year the company earned revenue of $12.68 billion and had a net profit of $7.68 billion.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.